Due to differing blast percentage criteria, three patients identified as AML with CEBPA mutation in the basic leucine zipper domain per ICC were placed in MDS-IB2 (14.5%, 15.2%, 19% blasts in BM) as per WHO-2022 criteria (Table 1, Fig. 1). This evidence concerns the gene CEBPA and myelodysplastic syndrome.